Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential ...

CLL-related immune dysfunction, along with therapy-associated immunosuppression, contributes to impaired tumor surveillance.

Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

Aging and CLL amplify fatigue, anemia, and infection risks, impacting physical activity and recovery. Tailored strategies, such as anti-inflammatory diets and strength training, can enhance resilience ...

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

LOS ANGELES--(BUSINESS WIRE)--City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose Los Angeles comprehensive cancer center is ...

Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and laboratory footprint. The study confirms reliable somatic hypermutation status ...